Vivek Subbiah: Our amazing CSO Dr. Spigel will be presenting at the big plenary!
Vivek Subbiah shared on X/Twitter:
“ASCO24 Sunday morning!
Starting the day with Skip Burris, Conquer Cancer, the ASCO Foundation and David R. Spigel.
Big day for small cell lung cancer.
Our amazing CSO Sarah Cannon Docs Dr. Spigel will be presenting at the big plenary!
LBA5 ADRIATIC: Durva after CRT in LS-SCLC
Primary OS and PFS
NCT03703297
SCRI – Today’s trials tomorrow’s therapies.”
Further information.
Source: Vivek Subbiah/X
Vivek Subbiah is the Chief of Early-Phase Drug Development at the Sarah Cannon Research Institute (USA). He is the former Executive Director of Oncology Research at the MD Anderson Cancer Network and a former Associate Professor in the Department of Investigational Cancer Therapeutics at The University of Texas MD Anderson Cancer Center.
Dr. Vivek Subbiah has served as the principal investigator in over 100 phase I/II trials and co-investigator in over 200 clinical trials and is known for his leadership in several first-in-human and practice-changing studies that directly led to approvals from the FDA, European Medicines Agency, and other agencies across the world.
He is an expert in tumor agnostic precision oncology and leads the BRAF and RET tissue agnostic studies to FDA approval.